secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0000950170-25-036822
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Therapeutics FY2024 net loss $78.3M; RAP-219 epilepsy trial top line Q3 2025
--------------------------------------------------------------------------------

- Net loss $78.3M for FY2024 vs $34.8M in FY2023; R&D expense $60.9M up from $28.0M.
- Phase 2a trial of RAP-219 in refractory focal epilepsy topline results expected Q3 2025 (narrowed timeline).
- Appointed Jeffrey Sevigny, M.D., as chief medical officer, effective immediately.
- Cash and investments $305.3M at year-end; expected to fund operations through end of 2026.
- FDA placed IND for Phase 2a DPNP trial on clinical hold; company finalizing trial plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/0000950170-25-036822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-20250311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer